Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 60

Results For "air"

2336 News Found

Merck presents new data on cardiovascular disease at ESC Congress 2025
News | August 26, 2025

Merck presents new data on cardiovascular disease at ESC Congress 2025

Merck will share two oral presentations on ASCVD treatment patterns and patient burden


India releases first-ever National Guidelines/SOPs for animal blood transfusion and blood banks
News | August 26, 2025

India releases first-ever National Guidelines/SOPs for animal blood transfusion and blood banks

Guidelines aim to establish state-regulated veterinary blood banks


J&J  to invest $2 billion at CDMO Fujifilm’s new hub
News | August 25, 2025

J&J to invest $2 billion at CDMO Fujifilm’s new hub

Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.


GSK forays into oncology in India with Jemperli and Zejula
News | August 25, 2025

GSK forays into oncology in India with Jemperli and Zejula

The company is bringing precision therapies for gynaecological cancers


AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib
News | August 23, 2025

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study


SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
Healthcare | August 21, 2025

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction

The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries


AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
News | August 17, 2025

AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease

Phase 1 dosing is expected to finish by the end of 2025